Hologic to Acquire Biotheranostics, Leader in Molecular Tests for Breast and Metastatic Cancers, for Approximately $230 Million

BioTheranosticsAvery WilliamsJanuary 5, 20212021

Biotheranostics’ Breast Cancer Index IDEAL study expands clinical evidence for prediction of extended endocrine benefit to patients treated with aromatase inhibitors

BioTheranosticsAvery WilliamsOctober 29, 2020

Biotheranostics’ Breast Cancer Index® Recently Recognized in Two National Clinical Practice Guidelines

Clinical Practice Guidelines Recognize Breast Cancer Index Clinical Utility Spans the Treatment Continuum for Patients with Early-Stage Estrogen Receptor Positive (ER+) Disease

Breast Cancer Index Endorsed in National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Breast Cancer and American Society of Clinical Oncology (ASCO) Clinical Practice Guideline Focused Update

BioTheranosticsAvery WilliamsDecember 3, 20182018

New Data Affirms Value of Breast Cancer Index (BCI) in Identification of Early Stage ER+ Breast Cancer Patients Appropriate for Extended Endocrine Therapy (EET)

Biotheranostics, Inc. today announced new data from two new studies further demonstrating the importance of BCI in clinical practice. The studies are being presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago this week.

BioTheranosticsAvery WilliamsJune 6, 20172017

BioTheranostics Raises $32M from HealthQuest and Others

BioTheranostics, a leader in molecular diagnostics for cancer, today announced that it has closed a $32 million financing led by MVM Life Science Partners, with participation of Canepa Advanced Healthcare Fund and HealthQuest Capital. As a result of the financing, bioTheranostics will be spun out from bioMérieux, which will remain a minority shareholder, and operate as an independent company.

Read More →